Physician profile
Jean E Levin
NPI 1881794089
$14,690.47
in general payments reported to CMS, 2019-2025
59 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $798 · 2022: $1,602 · 2023: $3,329 · 2024: $7,130 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,463 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,950 · Travel and Lodging: $1,854 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,950.00 |
| Travel and Lodging | $1,854.38 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,474.35 | 2021-2025 | |
| Seagen INC. | $2,302.75 | 2021-2023 | Tukysa |
| Incyte Corporation | $664.95 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $594.57 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $525.49 | 2021-2025 | |
| Abbvie INC. | $448.14 | 2021-2025 | |
| Lilly USA, LLC | $369.32 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $304.37 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $267.90 | 2021-2025 | Rybrevant, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $252.21 | 2021-2025 | Ojjaara, Shingrix, Zejula |
| Eisai INC. | $231.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.46 | 2021-2025 | Fruzaqla, Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $200.65 | 2022-2025 | Opdivo, Augtyro |
| Genentech USA, INC. | $194.56 | 2021-2025 | Tecentriq, Polivy, Alecensa |
| Amgen INC. | $185.00 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $164.71 | 2021-2025 | Vyloy, Xtandi |
| Astrazeneca Pharmaceuticals Lp | $160.87 | 2021-2025 | Lynparza, Calquence |
| Aveo Pharmaceuticals, INC. | $110.82 | 2021-2024 | Fotivda |
| Celgene Corporation | $109.21 | 2021-2023 | Pomalyst, Reblozyl |
| Adc Therapeutics America, INC. | $107.84 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $100.05 | 2023-2025 | Orgovyx |
| Beigene USA, INC. | $99.06 | 2021-2024 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $97.12 | 2021-2024 | Tavalisse, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $95.15 | 2021-2025 | Ultomiris |
| Array Biopharma INC | $93.06 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Ipsen Biopharmaceuticals, INC | $92.31 | 2022-2025 | Onivyde |
| Tolmar, INC. | $77.36 | 2024-2025 | Eligard, Jatenzo, Rubraca |
| Genzyme Corporation | $73.21 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $72.89 | 2021-2023 | |
| Taiho Oncology, INC. | $69.99 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $66.27 | 2021-2024 | Libtayo |
| Blueprint Medicines Corporation | $59.58 | 2021-2023 | Ayvakit |
| Tersera Therapeutics LLC | $57.69 | 2022-2024 | Xermelo, Zoladex |
| Exelixis INC. | $56.50 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $50.31 | 2022-2025 | Besremi |
| Karyopharm Therapeutics INC. | $48.89 | 2021-2024 | Xpovio |
| Gilead Sciences, INC. | $48.69 | 2023-2025 | Trodelvy |
| Beone Medicines USA, INC. | $46.92 | 2025 | Brukinsa, Tevimbra |
| Tactile Systems Technology INC | $45.35 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $38.97 | 2023-2024 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $37.27 | 2021-2022 | |
| Myovant Sciences INC. | $32.86 | 2022 | |
| Stemline Therapeutics INC. | $32.50 | 2023 | Orserdu |
| Emd Serono, INC. | $31.78 | 2021-2023 | Bavencio |
| Sobi, INC | $31.00 | 2023-2025 | |
| Morphosys, US INC. | $29.78 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.52 | 2023 | Bracanalysis Cdx |
| Kyowa Kirin, INC. | $20.00 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2021 | |
| Servier Pharmaceuticals LLC | $19.17 | 2025 | |
| G1 Therapeutics, INC. | $17.95 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.00 | 2024 | Xarelto |
| Novocure INC. | $15.00 | 2025 | Optune Lua (Novottf-200t) |
| Foundation Medicine, INC. | $14.55 | 2022 | |
| Pharmaand Gmbh | $13.79 | 2025 | Rubraca |
| Mirati Therapeutics, INC. | $13.65 | 2023 | Krazati |
| Acrotech Biopharma INC. | $13.39 | 2022 | |
| Acceleron Pharma, INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.